(Q33546321)

27 July 2017

1 reference

title

Acquired factor V inhibitors (English)

1 reference

27 July 2017

Knöbl P

1

1 reference

PubMed ID

10097809

27 July 2017

Lechner K

series ordinal

2

1 reference

27 July 2017

1 June 1998

1 reference

Best Practice and Research: Clinical Haematology

27 July 2017

1 reference

27 July 2017

11

1 reference

27 July 2017

305-318

1 reference

27 July 2017

2

1 reference

Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Postextraction bleeding in a patient with an acquired circulating anticoagulant against factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Acquired factor V inhibitor in a patient with acquired human immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Factor V inhibitor and bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

A case of factor V inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Hemorrhagic death associated with a high titer factor V inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

A factor V inhibitor: In vitro interference by calcium

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Observations on a Factor-V Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Development of a factor V and thrombin inhibitor following partial hepatic resection and the use of topical thrombin concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Factor V Inhibitor: Report of a Case, with Comments on a Possible Effect of Streptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Factor V anticoagulants: clinical, biochemical, and immunological observations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Multimodality therapy of an acquired factor V inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Bleeding due to an acquired inhibitor of platelet associated factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

A circulating anticoagulant specific for factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

[Isolated factor V deficiency caused by a specific inhibitor]

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

[Study of the inhibitor of familial factor V deficiency. II].

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Development of Antibodies to Bovine and Human Factor V in Two Children After Exposure to Topical Bovine Thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Factor V inhibitor in thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Factor V inhibitor associated with Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Factor V antibody and disseminated intravascular coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

A Specific Inhibitor of Human Clotting Factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

A circulating anticoagulant against factor V.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

[Occurrence of a circulating anticoagulant, factor V inhibitor after surgical intervention]

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Isolation and study of an acquired inhibitor of human coagulation factor V.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Massive hemorrhage associated with circulating antibodies to factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Clinical Significance of Antibodies to Bovine and Human Thrombin and Factor V After Surgical Use of Bovine Thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Severe bleeding caused by an inhibitor to coagulation factor V: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

A Circulating Factor V Inhibitor: Possible Side Effect of Treatment with Streptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Factor V inhibitor in celiac disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

The response of an acquired Factor V inhibitor to activated Factor IX concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980050-4

7 January 2021

10.1016/S0950-3536(98)80050-4

Identifiers

DOI

1 reference

27 July 2017

1 reference

PubMed ID

10097809